1Krouse RS. Surgical palliation of bowel obstruction [J]. Gastroenterol Clin North Am, 2006,35:143-151.
2Mercadante S, Casuccio A, Mangione S. Medical treatment for inop- erable malignant bowel obstruction: a qualitative systematic review.J Pain Symptom Manage, 2007; 33: 217-223.
3Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal ob- struction using octreotide. Eur J Cancer,1994,30A:28-30.
4Mystakidou K, Tsilika E, Kalaidopoulou O, et al.Comparison of oc- treotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized,double-blind, controlled clinical trial. Anticancer Res, 2002, 22: 1187-1192.
5Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol, 1996, 61: 345-348.
6Ripamonti C, Mercadante S, Groff L, et al. A role of octreotide, scopo- lamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage, 2000, 19:23-34.
7Mercadante S, Ripamonti C, Casuccio A, et al.Comparison of oc-treotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer, 2000,8:188-191.
8Matulonis UA,Seiden MV,Roche M,et al.Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.J Pain Sympotom Manage,2005,30:563-569.
9Giannetti N, Enjalbert A, Krantic S. Somatostatin analog SMS201995 inhibit s proliferation in human leukemia T cell line: relevance of the adenylyl cyclase stimulation [J]. J Cell Biochem, 2000, 78(4):666--673.
10Burghardt B, Barabas K, Marcsek Z, et al. Inhibitory effect of a long acting somatostatin analogue on EGF stimulated cell proliferation in Capan cells [J]. J Physiol Paris, 2000, 94(1):57-62.
